CLINICAL TRIAL STUDY
Fractional Carbon-Dioxide Laser Plus Topical Clotrimazole versus Oral Itraconazole plus Topical Clotrimazole for Onychomycosis: A Randomized, Controlled Trial
Tro V. Chau¹, Long P. Mai¹ *, Hao T. Nguyen², Suong M. Nay¹, Huyen T.N. Nguyen¹ and Thang T. Nguyen³

¹Department of Dermatology, Pham Ngoc Thach University of Medicine, Ho Chi Minh City, Vietnam
²Ho Chi Minh City Hospital of Dermato-Venereology, Ho Chi Minh City, Vietnam
³Department of Dermatology, University of Medicine and Pharmacy, Ho Chi Minh City, Vietnam

Abstract:
Background: Treating onychomycosis is problematic for a variety of reasons. The very nature of the hard, protective nail plate itself makes it difficult for topical drugs to reach the fungal pathogens beneath it. Oral therapy is more effective than topical therapy, but it is expensive, requires monitoring for toxicity, and can result in multiple drug interactions.

Objectives: To compare the efficacy and safety of fractional CO₂ laser combined with topical clotrimazole to oral itraconazole plus topical clotrimazole in the treatment of onychomycosis.

Methods: A sample of 88 adults (between the ages of 18 and 78) was randomly divided into two groups. 45 patients received fractional CO₂ laser therapy at an interval of 2 weeks and twice-daily application of clotrimazole 1% cream. 43 patients were treated by pulsed itraconazole (200 mg twice daily, 1 week on, 3 weeks off) and twice-daily application of clotrimazole 1% cream. The duration of the treatment was 3 months for fingernails and 4 months for toenails in both groups. The clinical effect was measured using the Scoring Clinical Index for Onychomycosis (SCIO index), KOH examination for the affected nails were performed, and liver function tests in the two groups were analyzed.

Results: 73% of patients treated with fractional ablative CO₂ laser achieved a negative KOH examination compared with 79% of the itraconazole group (P>0.05). The SCIO reduction in the laser group was superior to that in the itraconazole group (P<0.001). Notably, a biochemical abnormality was not documented in patients who received laser treatment. In contrast, liver transaminases elevations without clinical symptoms were documented in two patients at the end of itraconazole therapy.

Conclusion: Fractional CO₂ laser plus a topical antifungal drug might be more clinically effective in the treatment of onychomycosis than itraconazole, without any adverse reactions. It could be an alternative for clinicians in onychomycosis cases in which oral antifungal agents are contraindicated.

Keywords: Fractional carbon-dioxide laser, Topical clotrimazole, Oral itraconazole, Dermatophytes, Onychomycosis, Antifungal drug, Antifungal agents.

1. INTRODUCTION
Onychomycosis is a fungal nail infection either caused by a dermatophyte (tinea unguium) or by other non-dermatophyte filamentous fungi or Candida spp [1]. Onychomycosis is a common condition accounting for about 50% of all nail problems [2, 3] with a worldwide prevalence of 5.5% (based on a weighted average of 6 epidemiologic studies published in 2016) [4 - 9]. The prevalence increases with age [10]. Onychomycosis is a cosmetically disfiguring and debilitating disease adversely affecting the self-esteem of patients and
Treating onychomycosis is problematic for a variety of reasons. Oral therapy is more effective than topical therapy, but it is expensive, requires monitoring for toxicity, and can result in multiple drug interactions. Topical therapy is a long process that often requires nail debridement and multiple return visits and still delivers a relatively poor success rate. The very nature of the hard, protective nail plate itself makes it difficult for topical drugs to reach the fungal pathogens beneath it [12, 13]. Surgical nail avulsion for the treatment of onychomycosis should be avoided as potential side effects include postoperative pain, narrowing of the nail bed, distal paronychia, and infection [14]. It is contraindicated for patients with diabetes mellitus, peripheral and collagen vascular diseases, autoimmune disorders, disorders of hemostasis, and paronychia. Moreover, recurrences and reinnfection are not uncommon (up to 20% of cured patients) [10]. Long-term negative effects on quality of life, difficult management associated with a high prevalence of onychomycosis show the need for new treatment modalities.

Recently, there has been a growing interest in the laser industry following a series of scientific trials that have introduced various laser systems as a therapeutic alternative for this condition. Lasers are potential therapeutic modalities for onychomycosis because they have very few contraindications, minimal adverse effects, short treatment regimens, and good patient compliance [15]. The CO₂ laser system was the first laser device studied for onychomycosis. Tissue heating from laser machines can produce direct damage or induce an immune reaction against pathogens [16 - 18]. Furthermore, they have been studied as adjuvants to topical therapies for onychomycosis, as they can facilitate drug delivery through the nail plate by increasing permeability [19]. Ablative standard CO₂ in combination with a topical antifungal drug, proved to be efficacious [20, 21]. However, patients experienced pain for weeks after treatment [22]. Yang et al. [23] used the ablative fractional CO₂ laser for onychomycosis patients for 12 weeks with 8 sessions. The results showed clinical efficacy in 52%. Moreover, two other studies used fractional CO₂ laser plus a topical medication (amorolfine and terbinafine, respectively) for onychomycosis treatment. The clinical efficacy was 71% and 73%, respectively [24, 25]. These results suggested that a combination of ablative fractional CO₂ with topical antifungals could be more effective than fractional CO₂ therapy alone. However, no randomized trial comparing this treatment approach to standard systemic antifungal therapy.

Therefore, we designed a randomized, controlled study to compare the safety and efficacy of carbon dioxide laser-assisted delivery of topical clotrimazole with systemic itraconazole plus topical clotrimazole in the treatment of onychomycosis.

2. MATERIALS AND METHOD

2.1. Patients

This study was performed at Thu Duc General Hospital, Ho Chi Minh, Vietnam, between September 2018 and June 2019. The study was conducted with approval from the Thu Duc General Hospital ethics committee. The study protocol conformed to the guidelines of the Declaration of Helsinki. Written informed consent was obtained from all study participants before enrolment. As part of the consent process, clinical study participants were informed about the risks and benefits of participating in the study.

Adults (aged ≥ 18 years) who were capable of giving written informed consent and who had a clinical diagnosis of onychomycosis were eligible. Suspected onychomycosis was confirmed by positive direct microscopy in all patients.

Patients were excluded if they were pregnant, lactating or had other nail diseases or history of systemic antifungal treatment within the last 6 months.

The participants’ clinical history was reviewed in detail, including age, sex, duration of disease, first anatomic site affected at the onset of the disease, drug intake, and complete physical examination.

2.2. Study Design

Patients were randomized into two groups (laser group and itraconazole group) using a computer randomization program.

Patients in the laser group were treated with fractional CO₂ laser therapy (Lutronic, Korea) at an interval of 2 weeks with deep mode, pulse energy of 10 to 15 mJ, a density 10%, a pulse interval of 0.5 ms, and pulse width of 0.5 to 1.0 ms. The fluence was adjusted according to the thickness of the nail.

Patients in the itraconazole group received pulse itraconazole (200 mg twice per day, 1 week each month).

All subjects in the two groups received topical clotrimazole 1% cream twice daily. The duration of the treatment was 3 months for fingernails and 4 months for toenails in both groups.

2.3. Outcome Assessment

Direct examination with KOH was performed at the beginning and the end of the study. The results were counted as positive when specimens from the nail contained septated hyphae.

Clinical improvement, the Scoring Clinical Index for Onychomycosis (SCIO index), was evaluated by two experienced dermatologists before and after treatment. SCIO (range 1-30) was calculated using the clinical index component and the growth component in the following equation [26]:

\[
\text{SCIO} = \left( \frac{d}{3} \right)^{3.7} \left( f + h (3-f) \right) (l) (a + 3)/3 \right]^{1.2} \left( 1.2 \right)
\]

Where d = depth of involvement, f = clinical form, h = degree of hyperkeratosis, l = location, and a = age of patients. Digital photography documentation of nails was taken at
baseline and every visit. At the last visit, the patient's satisfaction with the treatment results was evaluated by a questionnaire using a grading system as follows: very satisfied, satisfied, slightly satisfied, and dissatisfied.

For the safety evaluation, we determined whether the subjects had any subjective symptoms or objective findings. Liver transaminases were performed before, and at the end of the therapy, other investigations were performed only if clinically demanded.

2.4. Statistical Analysis

Statistical analysis was carried out using SPSS version 24.0 for Windows (IBM, Armonk, NY, U.S.A.). All quantitative variables were expressed using measures of central tendency (mean, median) and measures of dispersion (SD). The normality of the data was checked using the Kolmogorov–Smirnov test. Comparisons were made using the Student t-test for normal distributions, and the Mann–Whitney test for non-parametric variables. Qualitative or categorical variables were described as frequencies and proportions. Differences in categorical variables were compared using the chi-square test. All statistical tests were two-sided and performed at a significance level of p < 0.05.

3. RESULTS

3.1. Demographics and Baseline Characteristics

In total, 88 patients were randomized and included in the study. 45 participants received fractional CO₂ laser therapy plus topical clotrimazole and 43 patients received oral itraconazole in combination with topical clotrimazole. Patient demographics and baseline characteristics are shown in Table 1. The comparison of gender, mean age, and mean disease duration at the first visit between the two groups showed no significant difference (p < 0.05).

Table 1. Baseline patient data.

|                  | Laser (n=45) | Itraconazole (n=43) |
|------------------|--------------|---------------------|
| **Sex N (%)**    |              |                     |
| Male             | 19 (42.2%)   | 16 (37.2%)          |
| Female           | 26 (57.8%)   | 27 (62.8%)          |
| **Age, y mean (95% CI)** | 46.5 (42.8 - 50.2) | 48.3 (44.6 - 51.9) |
| **Nail involvement N (%)** |              |                     |
| Toenail          | 139 (72%)    | 77 (60.6%)          |
| Fingernail       | 54 (28%)     | 50 (39.4%)          |
| **Duration of onychomycosis, months mean (95% CI)** | 14.4 (8.8 - 20) | 12 (8.5 - 15.5) |
| History of oral therapy N (%) | 14 (31.1%) | 7 (16.3%) |

3.2. Mycological Cure

At the end of the treatment period, direct microscopy was negative in 34 patients (79.1%) in the itraconazole group compared to 33 patients (73.3%) in the laser group (Table 2). This difference was not statistically significant (P=0.53).

3.3. Clinical Improvement

Among patients treated with fractional CO₂ laser, the baseline mean SCIO was 7.5 (95% CI 5.4 to 9.6) and the mean SCIO decreased to 2.4 (95% CI 0.7 to 4.1) at the end of the treatment. For itraconazole treated patients, the baseline mean SCIO was 5.9 (95% CI 3.9 to 7.9) and decreased to 3.9 (95% CI 1.9 to 5.9) at the last visit. At the end of the study, both groups had statistically significant reductions of mean SCIO compared with the first visit (both p<0.01) (Fig. 1).

Table 2. Direct microscopy results of the two treatment groups.

|                  | Laser | Itraconazole |
|------------------|-------|--------------|
| **Negative**     | 33 (73.3%) | 34 (79.1%)  |
| **Positive**     | 12 (26.7%) | 9 (20.9%)   |
| **p-value**      | 0.53  |              |

Furthermore, the difference between the mean SCIO at baseline and the end of the study was compared between the two groups. Results showed that the reductions in the mean SCIO in the fractional CO₂ laser-treated group was significantly greater than in the itraconazole-treated group (p<0.001) (Fig. 2).

3.4. Safety and Tolerability

Side effects were seen in 8 of 43 participants in the itraconazole- treated group. Side effects in the itraconazole-treated group were gastrointestinal effects (three patients), abdominal pain (one) headache (two), and asymptomatic self-
limited liver transaminases elevations (two). In contrast, several participants experienced a slight pain with CO₂ fractional therapy. No other adverse reactions were noted in the laser-treated group.

4. DISCUSSION

Up-to-date oral and topical antifungal agents (used alone or in combination) are considered the mainstay of therapy against onychomycosis. Even in the most experienced hands, these approved and widely used drugs may offer only disappointing results with high rates of relapse. Laser treatments are the most rapidly expanding area of onychomycosis therapy. Laser devices can be used to enhance drug delivery, activate topically applied drugs, or photothermally kill fungi. Laser treatments have a number of advantages over traditional therapy as they are primarily conducted in the clinic by trained professionals, reducing the need for patient compliance. They also have the potential to reduce adverse events and systemic interactions. To our knowledge, this study is the first controlled trial that compares the efficacy and safety of carbon dioxide laser-assisted delivery of topical clotrimazole to systemic itraconazole for onychomycosis treatment.

In the present study, there was more female than male patients (60% versus 40%). Similar results were found by previous studies [7, 9, 27, 28]. The difference might result from daily habits such as nail cosmetics, frequent water contact, detergents, raw food, cleaning materials, hydrocarbons, and trauma. The habit of sharing nail care equipment such as scissors, clippers, and emery boards in nail salons also contributes to the spread of infection [29 - 32].

In our study, onychomycosis involving toenails is about two times more common than that of fingernails. These findings are comparable to the results of a multicenter survey of 15,000 patients in Canada [3]. The warm, moist, confined environment provided by our occlusive footwear, combined with slower toenail than fingernail growth and less blood flow to the area, all combine to make the feet and toes specifically vulnerable.

Distal and lateral subungual onychomycosis was the most common pattern of onychomycosis in our study, followed by total dystrophic onychomycosis. A similar result was found in the studies of Gupta et al. [3], the largest epidemiology survey has reported.

We found no significant differences between laser and itraconazole group in the mycological clearance rate defined by negative KOH examination at the end of the study (73.3% vs. 79.1%).

However, the laser group showed a significantly higher clinical improvement defined as a reduction in the mean SCIO at the end of the study compared with the itraconazole group (P<0.001).

A few uncontrolled studies with a combination of fractional CO₂ laser and a topical antifungal drug have been done. Lim et al. [24] was the first group using the combination of fractional CO₂ laser and a topical antifungal agent for the management of onychomycosis. They treated 119 nails in 24 patients with fractional CO₂ laser and topical amorolfine. The fluence used was at 24 J/cm². The laser treatment consisted of three sessions at four-week intervals. Ninety-two percent of the patients showed a clinical response and 50% showed a complete response with a negative KOH. Similarly, Bhatta et al. [25] used fractional CO₂ laser (also three sessions at four-week intervals) combined with daily 1% terbinafine cream for the treatment of onychomycosis. The authors reported 95% negative KOH and 92% negative culture at the end of the study. Most laser-treated nails (98%) showed improvement: the mean SCIO was significantly decreased.

To date, the exact mechanism of action of laser devices against fungal pathogens is still under investigation. Fungal inactivation through unselective tissue heating is the most prevailing hypothesis. It has been reported that temperatures of 55°C are the lowest capable of destroying dermatophytes [16], whereas temperatures of less than 45°C can stimulate germination with *Trichophyton* spp.-specific optimal values [17]. Tissue heating can produce direct damage or induce an immune reaction against pathogens. The optimal temperature and duration of heating tolerated by human tissue have not been elucidated yet. Nevertheless, heating should be done cautiously as temperatures above 60°C, which lead to protein denaturation and coagulation of healthy surrounding tissue. Carney et al. [18] showed that heat produced a fungicidal effect for *T. rubrum* at 50°C with exposure times of 15 min, for *Epidermophyton floccosum* at 50°C with exposure times of 10 min, and limited growth of *Scytalidium* spp. was seen at 55°C with exposure times of 5 min. Additionally, the fractional CO₂ laser can create multiple tiny columns that facilitate drug delivery through the nail plate by increasing permeability [24]. Furthermore, during the laser procedure, nail plates, the environment for fungal growth, are partially vaporized [33].

In total, 11 adverse events related to itraconazole were experienced by 8 patients. The most frequently reported itraconazole-related adverse events were gastrointestinal disorders. Patients treated by fractional CO₂ laser only experienced slight pain. This correlates with most published studies [24, 25, 34, 35].

CONCLUSION

Fractional CO₂ laser combined with topical clotrimazole 1% is a safe and effective treatment option for onychomycosis. It achieved a greater clinical improvement with a similar mycotic cure rate rather than oral itraconazole in combination with topical clotrimazole 1%. Candidates for this method are patients who have failed previous therapies or those in whom systemic therapies are contraindicated, fearing polypharmacy, or drug interactions. Patients with certain non-dermatophyte molds, such as *N. dimidiatum* infections, in whom there is no good alternative therapy, may also be considered ideal candidates.

ETHICS APPROVAL AND CONSENT TO PARTICIPATE

The study was conducted with approval from the ethics committee of the Thu Duc General Hospital, Vietnam under approval no. 62.72.35.01.
REFERENCES

1. Zaia M, Lamberti M, De Angelis M, Cullina EA, Mezzapesa L. The role of Candida dermatitidis in onychomycosis. Mycoses 2019; 62(5): 315-20. [PMID: 30381293] [PMID: 30872784]

2. Faergemann J, Baran R. Epidemiology, clinical presentation and diagnosis of onychomycosis. Br J Dermatol 2003; 149(Suppl. 65): 1-4. [PMID: 14510968]

3. Gupta AK, Jain HC, Lynde CW, Macdonald P, Cooper EA, Summerbell RC. Prevalence and epidemiology of onychomycosis in patients visiting physicians’ offices: A multicenter canadian survey of 15,000 patients. J Am Acad Dermatol 2000; 43(2 Pt 1): 244-8. [PMID: 10906646]

4. Totri CR, Feldstein S, Admani S, Friedlander SF, Eichenfield LF. Epidemiologic analysis of onychomycosis in the san diego pediatric population. Pediatr Dermatol 2017; 34(1): 46-9. [PMID: 2799839]

5. Gupta AK, Gupta G, Jain HC, et al. The prevalence of unsuspected onychomycosis and its causative organisms in a multicentre Canadian sample of 30 000 patients visiting physicians’ offices. J Eur Acad Dermatol Venereol 2016; 30(9): 1567-72. [PMID: 27168494]

6. Gupta C, Jongman M, Das S, et al. Genotyping and In Vitro Antifungal Susceptibility Testing of Fusarium Isolates from Onychomycosis in India. Mycoses 2016; 59(12): 798-802. [PMID: 27342461]

7. Maraki S, Mavromanolaki VE. Epidemiology of onychomycosis in Crete, Greece: a 12-year study. Mycoses 2016; 59(12): 798-802. [PMID: 27435233]

8. Otašević S, Barac A, Pekmezović M, et al. The prevalence of Candida onychomycosis in Southeastern Serbia from 2011 to 2015. Mycoses 2016; 59(3): 167-72. [PMID: 27012984]

9. Dubljanić E, Džamić A, Vujičić I, et al. Epidemiology of onychomycosis in Serbia: A laboratory-based survey and risk factor identification. Mycoses 2017; 60(1): 25-32. [PMID: 27532417]

10. Scher RK, Baran R. Onychomycosis in clinical practice: Factors contributing to recurrence. Br J Dermatol 2003; 148(Suppl. 65): 5-8. [PMID: 14510969]

11. Gupta AK, Mays RR. The impact of onychomycosis on quality of life: A systematic review of the available literature. Skin Appendage Disord 2018; 4(4): 208-16. [PMID: 30410887]

12. Gupta AK, Mays RR, Versteeg SG, Shear NH, Piguet V. Update on current approaches to diagnosis and treatment of onychomycosis. Expert Rev Anti Infect Ther 2018; 16(12): 929-38. [PMID: 28047820] [PMID: 29503082]

13. Gupta AK, Versteeg SG, Shear NH. Onychomycosis in the 21st century: An update on diagnosis, epidemiology, and treatment. J Cutan Med Surg 2017; 21(6): 525-36. [PMID: 27911718] [PMID: 28169462]

14. Lai WY, Tang WY, Loo SK, Chan Y. Clinical characteristics and treatment outcomes of patients undergoing nail avulsion surgery for dystrophic nails. Hong Kong Med J 2011; 17(2): 127-31. [PMID: 21471592]

15. Francaziz W, Fritz K, Salastru C. Laser therapies for onychomycosis - critical evaluation of methods and effectiveness. J Eur Acad Dermatol Venereol 2016; 30(6): 936-42. [PMID: 26953542]

16. Engelhardt-Zaada C, Pochacki H. Influence of temperature on dermatophytes. Mycopathol Mycol Appl 1972; 48(4): 297-301. [PMID: 4617697]

17. Hashimoto T, Blumenthal HJ. Survival and resistance of Trichophyton mentagrophytes arthrospores. Appl Environ Microbiol 1978; 35(2): 274-7. [PMID: 1012840]

18. Carney C, Cantrell W, Warner J, Elewski B. Treatment of onychomycosis using a sublimisilise 1064-nm neodymium:yttrium-aluminum-garnet laser. J Am Acad Dermatol 2013; 69(A): 578-82. [PMID: 23566649]

19. Morais OO, Costa IMC, Gomes CM, Shizato DH, Ayres GMC, Cardoso RM. The use of the Er:YAG 2940nm laser associated with amorolfine lacquer in the treatment of onychomycosis. An Bras Dermatol 2013; 88(5): 845-9. [PMID: 24173203]

20. Apfelberg DB, Rothermel E, Wiatfeld A, Masar MR, Lash H. Preliminary report on use of carbon dioxide laser in podiatry. J Am Podiatry Assoc 1984; 74(10): 509-13. [PMID: 52670872]

21. Baden HP. Treatment of distal onychomycosis with avulsion and topical antifungal agents under occlusion. Arch Dermatol 1994; 130(5): 558-9. [PMID: 10010004]

22. Grover C, Bansal S, Sanda S, Reddy BS, Komar V. Combination of surgical avulsion and topical therapy for single nail onychomycosis: A randomized controlled trial. Br J Dermatol 2007; 157(2): 364-8. [PMID: 17573877]

23. Y Y H L, Y Y R. Efficacy of a superpulse-mode fractional carbon dioxide laser for the treatment of onychomycosis: A clinical observational study. Zhonghua Pifuke Zazhi 2015; 48(8): 526-30. [PMID: 23411647]

24. Lim EH, Kim HK, Park YO, et al. Toenail onychomycosis treated with a fractional carbon-dioxide laser and topical antifungal cream. J Am Acad Dermatol 2014; 70(5): 918-23. [PMID: 24858519]

25. Bhatta AK, Keyal U, Huang X, Zhao JJ. Fractional carbon-dioxide (CO2) laser-assisted topical therapy for the treatment of onychomycosis. J Am Acad Dermatol 2014; 70(5): 918-23. [PMID: 24858519]

26. Papini M, Piraccini BM, Difonso E, Brunori A. Epidemiology of onychomycosis in Italy: prevalence data and risk factor identification. Mycoses 2015; 58(11): 659-64. [PMID: 26412300]

27. Gasser J, Pagani E, Vittadello F, Nobile C, Zampieri P, Eisendle K. Frequency, type and treatment of fungal pathogens in toenail onychomycosis in the central Alpine region of South Tyrol, northern Italy - a 10-year retrospective study from 2004 to 2013. Mycoses 2016; 59(12): 798-802. [PMID: 27402003]

28. Scher RK, Rich P, Pariser D, Elewski B. The epidemiology, etiology, and pathophysiology of onychomycosis. Semin Cutan Med Surg 2013;
Fractional CO\textsubscript{2} Laser Plus Topical Clotrimazole versus Itraconazole for Onychomycosis

The Open Dermatology Journal, 2020, Volume 16

21

Havlickova B, Czaika VA, Friedrich M. Epidemiological trends in skin mycoses worldwide. Mycoses 2008; 51(Suppl. 4): 2-15.

Havlickova B, Czaika VA, Friedrich M. Epidemiological trends in skin mycoses worldwide. Mycoses 2008; 51(Suppl. 4): 2-15.

Nenoff P, Kruger C, Ginter-Hanselmayer G, Tietz HJ. Mycology - an update. Part 1: Dermatomycoses: causative agents, epidemiology, and pathogenesis. J Dtsch Dermatol Ges 2014; 12(3): 641-8.

Ghannoum MA, Hajjeh RA, Scher R, et al. A large-scale North American study of fungal isolates from nails: The frequency of onychomycosis, fungal distribution, and antifungal susceptibility patterns. J Am Acad Dermatol 2006; 43(4): 641-8.

Alam M, Pantanowitz L, Harton AM, Arndt KA, Dover JS. A prospective trial of fungal colonization after laser resurfacing of the face: Correlation between culture positivity and symptoms of pruritus. Dermatol Surg 2003; 29(3): 255-60.

Shi J, Li J, Huang H, et al. The efficacy of fractional carbon dioxide (CO\textsubscript{2}) laser combined with terbinafine hydrochloride 1% cream for the treatment of onychomycosis. J Cosmet Laser Ther 2017; 19(6): 353-9.

Zhou BR, Lu Y, Permatasari F, et al. The efficacy of fractional carbon dioxide (CO\textsubscript{2}) laser combined with luliconazole 1% cream for the treatment of onychomycosis: A randomized, controlled trial. Medicine (Baltimore) 2016; 95(44)e5141

© 2020 Van Chau et al.
This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: https://creativecommons.org/licenses/by/4.0/legalcode. This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.